Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Denali Therapeutics (DNLI) Shares Outstanding (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Shares Outstanding for 9 consecutive years, with $156.2 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 8.29% to $156.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $156.2 million through Dec 2025, up 8.29% year-over-year, with the annual reading at $156.2 million for FY2025, 8.29% up from the prior year.
  • Shares Outstanding for Q4 2025 was $156.2 million at Denali Therapeutics, up from $146.6 million in the prior quarter.
  • The five-year high for Shares Outstanding was $156.2 million in Q4 2025, with the low at $121.1 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $135.5 million, with a median of $137.7 million recorded in 2023.
  • The sharpest move saw Shares Outstanding rose 14.79% in 2021, then rose 1.34% in 2022.
  • Over 5 years, Shares Outstanding stood at $122.3 million in 2021, then increased by 11.19% to $136.0 million in 2022, then grew by 1.78% to $138.4 million in 2023, then grew by 4.22% to $144.2 million in 2024, then rose by 8.29% to $156.2 million in 2025.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $156.2 million, $146.6 million, and $145.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.